Ads
related to: anti mesothelin antibody
Search results
Results From The WOW.Com Content Network
Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. [1] It was developed by Morphotek, Inc. . Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.
Mesothelin is a 40 kDa protein that is expressed in mesothelial cells. [7] The protein was first identified by its reactivity with monoclonal antibody K1. [8] Subsequent cloning studies showed that the mesothelin gene encodes a precursor protein that is processed to yield mesothelin which is attached to the cell membrane by a glycophosphatidylinositol linkage and a 31-kDa shed fragment named ...
NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological cancers. NI-1801, an anti-CD47, anti-mesothelin bispecific antibody in the preclinical phase of development for treatment of solid tumors. [11] No drugs have been approved yet.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Another immunotoxin, SS1P, [18] targets the mesothelin antigen. Mesothelin was discovered by Pastan and his colleague Mark Willingham and is a promising target for cancer immunotherapy, because it is expressed on many cancers: mesothelioma, ovarian, lung, pancreatic stomach cancers and cholangiocarcinoma, but not on essential organs.
Investors including Amalgamated Bank and Dominican Sisters of Grand Rapids said Tuesday in a letter to Walmart CEO Doug McMillon that they are "concerned to see our company give into bullying and ...